Randomized, open-label, replicated single-dose, 4-period, 2-sequence crossover study to assess the comparative bioavailability of test product Amlodipine/Valsartan/Hydrochlorothiazide 10 mg/160 mg/12.5 mg film-coated tablets to reference product Exforge HCT 10 mg/160 mg/12.5 mg film-coated tablets in healthy male and female subjects under fasting conditions.

2025-523054-14-00 Human pharmacology (Phase I) - Bioequivalence study Ended

Start 15 Sep 2025 · End 9 Dec 2025 · Status Ended · 1 EU/EEA countries · 1 sites

Overview

Sponsor-declared trial summary

Phase Human pharmacology (Phase I) - Bioequivalence study
Status Ended
Participants planned 42
Countries 1
Sites 1

not applicable (submitted trial is bioavailability)

Key facts

Sponsor
Pharma Start LLC
Participant type
Healthy volunteers
Age range
18-64 years
Gender
Male and Female
Therapeutic area
Diseases [C] - Cardiovascular Diseases [C14]
Trial duration
15 Sep 2025 → 9 Dec 2025
Decision date (initial)
2025-08-28
Transition trial
No
Low-intervention
No
Rare-disease indication
No
Vulnerable population
Yes

Trial design

CTIS Part I — objectives, methods, condition coding

Conditions and MedDRA coding

not applicable (submitted trial is bioavailability)

VersionLevelCodeTermSystem organ class
20.0 SOC 10047065 Vascular disorders 12
21.1 PT 10015488 Essential hypertension 100000004866

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

Pharma Start LLC

Sponsor organisation
Pharma Start LLC
Address
Bulv. Havela Vatslava 8
City
Kyiv
Postcode
03124
Country
Ukraine

Scientific contact point

Organisation
Pharma Start LLC
Contact name
Anton Terentiev

Public contact point

Organisation
Pharma Start LLC
Contact name
Anton Terentiev

Locations

1 EU/EEA country · 1 investigational sites

By country

CountryMS statusPlanned subjectsSites
Czechia Ended 42 1
Rest of world 0

Investigational sites

Czechia

1 site · Ended
Quinta-Analytica s.r.o.
clinical unit, Prazska 1486/18c, Hostivar, Prague

Country notifications

Trial-start, recruitment-start, end and early-termination notifications submitted per Member State

Country Trial startTrial end Recruitment startRecruitment end Early termination
Czechia 2025-09-15 2025-12-09 2025-09-15 2025-09-27

Application history

3 submissions — initial application plus substantial / non-substantial modifications

#TypeCodeSubmittedReference MSConclusionDecision date
1 INITIAL IN 2025-07-25 Czechia Acceptable
2025-08-28
2025-08-28
2 NON SUBSTANTIAL MODIFICATION NSM-1 2025-09-01 Czechia Acceptable
2025-08-28
2025-09-01
3 NON SUBSTANTIAL MODIFICATION NSM-2 2025-12-02 Czechia Acceptable
2025-08-28
2025-12-02